Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of YG1699 in Patients With Diabetes and Kidney Dysfunction
NCT06648876Phase 1Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of YG1699 in diabetic kidney disease (DKD) (4 arms), sponsored by Renji Hospital. Primary endpoint: YG1699 concentration in plasma at 24 hours. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
YG1699
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06648876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06648876.